About Us
Founded in 2023 and headquartered in Hayward, California, we are a team of scientists and drug developers creating the next generation of best-in-class, multi-specific T-cell engagers (TCEs) to treat solid and hematologic tumors.
Driven by science, shaped by collaboration, and focused on impact—we create novel antibody therapeutics to transform patient futures.
At 92Bio, we are leveraging the latest advances in multi-specific antibody design and novel immune cell subsets to create fit-for-purpose TCEs. Our potentially best-in-class FRα x CD3 TCE, NTB-928, is on track to enter the clinic in the first half of 2026. We are also on the cutting edge of γδ T-cell activating therapy development. γδ T-cells are an enigmatic but powerful immune population strongly linked to favorable outcomes in cancer. Our first γδ T-cell engaging drug, for the treatment of acute myeloid leukemia, is slated to enter the clinic in 2027. Exciting future projects in solid and hematologic tumors are not far behind. We embrace the equal parts grit and enthusiasm required to turn this bold vision into real world impact.
But science is only part of who we are.
Ask our scientists: what sets 92Bio apart is our culture. We’re a close-knit, dynamic team fueled by collaboration, innovation, and trust. Our employees describe our environment as results-driven yet creative, inclusive and supportive; a place where clear-eyed engagement with risk is encouraged and professional growth is prioritized. We also believe in giving back, cultivating a strong spirit of community engagement and philanthropic impact.
